Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men.
In Ontario, persons with multiple sexual partners became eligible for free hepatitis B vaccine in late 1991. From January 1992 to January 1993, a sexually transmitted disease (STD) clinic for men in Toronto was one site where the vaccine was delivered. The objectives of the study were to determine the seroprevalence of hepatitis B markers, the series completion rate for hepatitis B vaccine, and the seroprevalence of hepatitis B markers required before screening would be a cost-effective endeavour. The seroprevalence of anti-HBs in gay/bisexual men was 18.1% (95% CI: 15.3%-20.7%) and in heterosexual men was 5.1% (95% CI: 3.0-9.7%). HBsAg was detected in 0.9% (95% CI: 0.04%-1.8%) of gay/bisexual men and was undetected in heterosexual men. Completion of a full vaccine series was 47% for gay/bisexual men and 25% for heterosexual men (p = 0.04). A combined seroprevalence of HBsAg and anti-HBs of at least 30-64%, depending on cost figures used, was required to justify screening prior to completion of a full series.
Yuan
L
L
Dept. of Preventive Medicine and Biostatistics, University of Toronto.
Robinson
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D003151:Community Health Centers; D003362:Cost-Benefit Analysis; D006509:Hepatitis B / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D009864:Ontario / Q000453:epidemiology; D015995:Prevalence; D015397:Program Evaluation; D011446:Prospective Studies; D016036:Seroepidemiologic Studies; D012725:Sexual Behavior; D012749:Sexually Transmitted Diseases / Q000150:complications* / Q000453:epidemiology; D014611:Vaccination / Q000191:economics / Q000592:standards*
D017325:Hepatitis B Vaccines